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To date in sub-Saharan Africa, schisto-
somiasis treatment and monitoring fo-
cuses on school-aged children, but
much less attention has been given to
preschool-aged children and adults.
Here, we summarize the distribution and
morbidity of schistosomiasis across
these age groups and highlight gaps in
current control strategies.
Preschool-aged children incur significant
morbidity but are systematically ex-
cluded fromcurrent treatment programs;Christina L. Faust,1,* Derick N.M. Osakunor,2 Jennifer A. Downs,3
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Despite accelerating progress towards schistosomiasis control in sub-Saharan
Africa, several age groups have been eclipsed by current treatment andmonitoring
strategies that mainly focus on school-aged children. As schistosomiasis poses a
threat to people of all ages, unfortunate gaps exist in current treatment coverage
and associated monitoring efforts, preventing subsequent health benefits to
preschool-aged children as well as certain adolescents and adults. Expanding ac-
cess to younger ages through the forthcoming pediatric praziquantel formulation
and improving treatment coverage in older ages is essential. This should occur
alongside formal inclusion of these groups in large-scale monitoring and evalua-
tion activities. Current omission of these age groups from treatment andmonitoring
exacerbates health inequities and has long-term consequences for sustainable
schistosomiasis control.inclusion in control programs could
have both short- and long-term health
benefits.
Mass drug administration must be im-
proved to reach at-risk adults. Low cov-
erage has cascading implications for
health, including morbidities specific to
reproductive ages, and can facilitate in-
fection with other diseases such as HIV.
Control and elimination of schistosomia-
sis will require future integration of all
age groups into treatment programs
and evaluation of progress.
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Diseases, Liverpool School of TropicalSuccesses andRemainingChallenges in Sub-SaharanAfrican Schistosomiasis Control
Schistosomiasis is a water-borne parasitic disease with over 220 million people infected in sub-
tropical and tropical regions across the globe, the vast majority of whom live in sub-Saharan
Africa [1]. For the last decade, the goal of the World Health Organization (WHO) has been to re-
duce schistosomiasis morbidity by this year (2020), and eliminate schistosomiasis as a public
health burden by 2025 ([2]; Box 1). The primary method for achieving these goals is preventive
chemotherapy (PC) (see Glossary) through mass drug administration (MDA) with the
anthelmintic praziquantel. These ambitious goals are underpinned by targets that require coun-
tries to reach at least 75% treatment coverage of school-aged children (SAC) and at-risk
adults, with MDA schedules and target groups depending on schistosomiasis endemicity [3]
(Figure 1). Data collated by WHO demonstrate that 46.3% of all people eligible and requiring
treatment globally in 2017 were reached, while coverage of just SAC was higher at 70.8%
[4]. Despite this progress, it is clear that access to praziquantel for SAC still falls short and
preschool-aged children (PSAC), certain adolescents, and adults are commonly omitted
from MDA campaigns.
Models show that high PC coverage in both SAC and at-risk adults is required for morbidity
control, particularly in high endemic areas [5,6]. Current programs do not always have complete
geographic coverage across endemic schistosomiasis regions (Figure 1B,C; [4,7]). Despite
this, empirical work demonstrates that WHO goals can be achieved in as little as a single MDA
round in low endemicity settings [8] but large-scale operational studies have also shown that per-
sistent transmission hotspots are a common occurrence [9,10]. Although progress is being
made, here we focus on highlighting the unique challenges to the control and management of
schistosomiasis in age groups beyond SAC with a focus on PSAC and adults, but with implica-
tions for control of schistosomiasis across all ages.582 Trends in Parasitology, July 2020, Vol. 36, No. 7 https://doi.org/10.1016/j.pt.2020.04.012
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Box 1. Neglected Tropical Disease (NTD) Roadmaps
NTDs are a diverse group of infections that impact the world’s poorest communities. TheWHO first convened Global Part-
ner Meetings in 2007 to help integrate strategies, goals, and targets across disease-control programmes. The roadmap
includes specific targets for each of the twenty NTDs. For schistosomiasis, the goal is to control the disease by 2020 (de-
fined as b5% heavy infection intensities across sites) and eliminate the disease as a public health problem by 2025 (defined
as b1% heavy infection intensity across sites). To achieve these goals, the WHO originally set a target of 75% treatment
coverage of SAC. A draft of the NTD Roadmap for 2021–2030 has just been published by the WHO and partners for fur-
ther consultations [12]. In the new roadmap, 'extending PC to all populations in need and ensuring access to the
necessary medicines' is critical action for schistosomiasis alongside more integrated control methods. These actions will
be necessary for achieving the ambitious goal of eliminating schistosomiasis as a public health problem (defined as b1%
proportion of heavy intensity infections) in all endemic countries by 2030). In this opinion article we argue that PSAC, ad-
olescents, pregnant women, and adults across many communities urgently require treatment to reduce individual morbid-
ity and improve PC efficacy.
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Trends in ParasitologyCurrently, schistosomiasis control in endemic regions relies on regular MDA and monitoring of in-
fections in SAC (Figure 1A,B). Overemphasis of treatment and evaluation in this limited age group
eclipses other high-risk groups and may lead to bounce backs later on [11]. As we enter the new
decade, the WHO and partners have put forward a draft of an updated Neglected Tropical Dis-
ease (NTD) roadmap for 2021–2030 [12] which includes new goals for schistosomiasis control
and elimination as a public health problem (Box 1). Despite heightened control efforts over the
past decade, the roadmap indicates that critical action is required for expanding PC to all popu-
lations at risk. In order to succeed across wide geographic areas, we argue that both control and
monitoring strategies should extend to all age groups such that no one with schistosomiasis is
systematically excluded. Here, we provide an evaluation of the epidemiological and clinical man-
ifestations of schistosomiasis in age groups beyond SAC, discuss their current inclusion in control
strategies, and highlight consequences of existing policies on health inequities.
Epidemiology of Schistosomiasis and Age Structures in the Era of MDA
Prevalence of schistosomiasis among SAC is used to establish endemicity and inform control strat-
egies [3]. This was initially justified by a series of studies that demonstrated that schistosomiasis in
SAC, particularly in children 9–12 years of age, positively correlated with the prevalence and inten-
sity across communities in a diversity of geographical and epidemiological settings [13]. However,
many of these studies were conducted before national MDA programs began, and as the burden
across a community is unevenly altered by ongoing control interventions a reappraisal of individuals
at risk, those requiring treatment, and those contributing to transmission is needed.
The age structure, or relative abundance of individuals in each age class, varies between coun-
tries and is dependent on birth and death rates. In many of the sub-Saharan African countries
which are highly endemic for schistosomiasis, high birth rates mean that PSAC, 1–4 years old,
can comprise up to 25% of the population ([14]; Figure 2A,B). Even in these rapidly growing pop-
ulations, adults are still the most abundant age group. Age prevalence and intensity curves vary
across endemicity areas, and are also likely altered by treatment history, particularly where that
treatment has repeatedly targeted only an age-specific subsection of the population.
Community members that aren’t covered in school-based MDA, including infants, PSAC,
nonenrolled school-aged children, and/or adults, could be important contributors to schistosome
transmission [15,16] (Figure 2C,D). Of the approximately 120 million children affected by schisto-
somiasis worldwide, it is estimated that approximately 50 million are PSAC [17–19]. Children
below 5 years of age are not regularly included in MDA campaigns [20], and drug licensing of
praziquantel only applies to individuals aged 4 years and above. In addition, certain adolescents
and adults, particularly those aged 16–25 years, can have mean infection intensities that are
higher than those of SAC [21–23], most commonly when their livelihoods put them in dailyTrends in Parasitology, July 2020, Vol. 36, No. 7 583
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Figure 1. Age Transitions across Lifetime and Treatment Interventions for Individuals in Schistosome Endemic Regions in sub-Saharan Africa. (A) Infants
(b1 year) and preschool-aged children (PSAC) (1–4 years) are currently not included in any mass drug administration (MDA). At-risk adults (N14 years) are included in MDA
only if the prevalence in school-aged children (SAC) is N50% (see endemicity in the Glossary). (B) Estimates of the percentage of SAC (here shown as 5–14 years) in sub-
Saharan African countries requiring schistosomiasis preventive chemotherapy (PC) (data from [7,14]). Red points indicate countries that gave PC to SAC in 2017 and/or
2018, the most recent reporting years. (C) Estimates of the percentage of adults (here shown as 15 years and older) in sub-Saharan African countries requiring schisto-
somiasis preventive chemotherapy. Red points indicate countries that gave PC to adults in 2017 and/or 2018, and white indicates no PC for adults. The absence of points
and shading indicate data not available (or outside sub-Saharan Africa).
Trends in Parasitologycontact with infectious water (e.g., car washing, fishing, housework in regions with limited access
to clean water) [24,25]. A recent systematic review of studies on MDA found that combined
MDA (community-based MDA supplemented with school-based MDA) had the highest
overall coverage in SAC, including unenrolled SAC, better than school-based MDA which had
the lowest overall coverage in SAC [26]. Because MDAs are targeted at a subset of the popula-
tion, this selective treatment can cause an age shift in prevalence and intensity of infection,
meaning that the burden of schistosomiasis accumulates at older ages with increasing school-584 Trends in Parasitology, July 2020, Vol. 36, No. 7
Glossary
Age structure: the age structure of a
country is defined by the proportion of
the population in different age classes.
The age structure of a country’s
population is determined by mean birth
and death rates at each age.
At-risk adults: adults that are
frequently exposed to unsafe water. This
can range from a subset of a community
that engages in economic and domestic
activities that put them in contact with
water to all adults in a community living
close to an infested water body. We use
'at-risk adults' and 'adults'
interchangeably in this piece.
Endemicity: categories of
schistosomiasis risk determined at the
community or regional level. The WHO
gives guidelines for three categories of
risk and the MDA schedules for each,
which is based on the prevalence in
school-aged children determined by
parasitological methods:
• Low endemicity: b10%. Recommend
treating all school-aged children twice
during primary school and having
praziquantel available at dispensaries
and clinics.
•Moderate endemicity: N10%but b50%.
Recommend treating school-age children
and adults at risk once every 2 years.
• High endemicity: N 50%. Recommend
treating school-age children and all
adults at risk once a year.
Geographic coverage: the proportion
of endemic country implementation units
(usually districts or states) that are
reached in a given round of MDA.
Health inequity: a systematic
difference in health based on
demographics or social status (such as
age group).
Infants: usually defined as children
under 1 year of age. Not the focus of
this paper as there are currently
limited schistosomiasis treatment
options, even in the pipeline, for this
age category.
Intensity of infection: the infection
intensity of schistosome infections is
indirectly measured by counting the
number of eggs excreted in feces
(expressed as eggs per gram, epg) or in
urine (expressed as eggs per 10 ml of
urine), depending on the species.
Infection intensity of intestinal
schistosomiasis is defined as light
intensity (0–99 epg), moderate intensity
(100–399 epg) or heavy intensity (N400
epg). Infection intensity of urogenital
schistosomiasis is defined as light
Trends in Parasitologybased MDA or higher coverage in SAC during community-based MDA [5], though the effect at
larger scales still needs to be investigated. Regardless, theoretical work has underscored the im-
portance of quantifying infections across all community members to design the most effective
control and monitoring programs for schistosomiasis [6].
PSAC Are Still Excluded from MDAs
Despite recommendations by the WHO in 2010 to treat 2- and 3-year-old PSAC with
praziquantel in off-licence settings [17], guidelines are difficult to implement. Praziquantel is only
formally licensed for 4-year-olds and above, and the global community continues to discuss
the best tools and approaches for targeting this age group. Reasons for PSAC exclusion from
MDA are wide ranging and include operational difficulties in access and diagnosis, inadequate
knowledge about risk and infection burden, and lack of a pediatric formulation of the drug
praziquantel for treatment of this age group [27] (Box 2).
We now know that schistosome infection can occur with water contact immediately after birth
[20,28–30], and that the intensity of infection continues to accumulate until a child’s first
praziquantel treatment at age 5 years or older during MDA. This age group can have prevalence
rates exceeding 50%, and intensities of over 400 eggs per gram (epg) of stool have been de-
tected in children as young as 2 years [31,32]. Such heavy infections in PSAC reduce physical
and cognitive development and, when persistently untreated, can lead to severe morbidity, and
in serious cases, mortality [33]. Given the opportunity to influence overall future health in infants
and young children, repeated treatment in these groups could provide lasting health benefits
[34]. Praziquantel treatment has been shown to significantly reduce schistosome-associated pro-
teinuria, albuminuria, and microhaematuria in PSAC [34]. Children 5 years of age and below can
develop microhaematuria as soon as 3 months after exposure, and existing tools are suitable for
diagnosis [35]. Promisingly, this early morbidity resolves within 3 months of a single dose of
praziquantel treatment [35]. More chronic effects on growth and development, for example
stunting, may be irreversible if infection is left untreated for longer periods. To help mitigate this,
experimental modelling suggests that repetitive treatment before reaching school age (~6 years
of age) can facilitate 'catch-up growth' [36]. However, current exclusion of this age group from
MDA programs creates a serious health inequity, particularly in high-endemicity areas
[27,37,38]. By leaving this age group untreated, PSAC are systematically excluded from the ben-
efits of treatment, leading to accumulation of morbidity that can become irreversible, an unac-
ceptable health deficit unparalleled in any other parasitic disease.
A well known deficit of praziquantel is that treatment does not prevent reinfection(s), which upon
subsequent water contact and exposure leads to recurring infection and progressive morbidity
[39,40]. However, treatment of schistosome infections can induce protective immune responses
against reinfection [41–43], and an increase in post-praziquantel immune responses are associ-
ated with reduced reinfection levels in PSAC [44]. In addition, evidence from experimental studies
suggests that treating short duration infections provides greater levels of protection against rein-
fection compared with immunity developed through treatment of longer, more chronic infections
[45,46]. Therefore, early treatment of schistosome infections in PSAC can be further justified to
reduce reinfections and associated long-term morbidity.
Opportunities for Interventions in PSAC
If we are to deliver sustainable schistosomiasis elimination programs, treatment of PSAC needs to
be prioritized. There are major unanswered questions: how do we quantify infection in this age
group, and more importantly, unlike SAC, who typically are easily reached through school-
based programs, how do we access these younger children and at what frequency [17,47]? ATrends in Parasitology, July 2020, Vol. 36, No. 7 585
intensity (1–50 eggs per 10 ml) or heavy
intensity (N50 eggs per 10 ml).
Mass drug administration (MDA):
the administration of treatment
(praziquantel for schistosomiasis) to
every member of a defined population,
irrespective of individual infection status.
• School-based MDA: praziquantel
(for schistosomiasis) only distributed at
schools (usually primary schools, but
sometimes also secondary schools).
• Community-based MDA:
praziquantel (for schistosomiasis)
distributed to community members
deemed to be at risk – usually all school-
aged children (SAC) and at-risk adults.
Recommended door-to-door
administration but can also be, and
usually is, distributed centrally.
• Combined MDA: praziquantel (for
schistosomiasis) distributed to
community members deemed to be at
risk and at schools.
Preschool-aged children (PSAC):
individuals that are here defined as
children between 1 and 4 years of age,
but the specific range can vary by
location (sometimes 1–5 years old). We
include toddlers (1–2 years of age) in
PSAC as these ages are included in the
pediatric praziquantel formulation
(Box 2).
Preventive chemotherapy (PC): the
use of safe, effective drugs to treat
populations at risk to prevent morbidity.
School-aged children (SAC):
individuals that are usually defined as
children between 5 and 14 years of age,
but the specific range can vary by
location. These children are usually
eligible to attend primary school.
However, all children in this age range –
both enrolled and unenrolled in school –
are part of this group regardless of their
school enrolment or attendance.
Nonenrolled SAC are also often
neglected in school-based MDA
campaigns.
Treatment coverage: the proportion
of eligible individuals (above the age of 5
years and/or SAC based on MDA
guidelines) that take praziquantel in a
given round of MDA.
Trends in Parasitology'test and treat' approach for PSAC [17,48] – pending roll-out of the pediatric praziquantel formu-
lation – could significantly reduce infection and disease burden in this age group. If PSAC treat-
ment falls within MDA, it will be important to estimate the infection burden in PSAC to identify
focal areas where treatment is needed most [48]. The frequency of treatment could follow guide-
lines set by the WHO, but whether or not endemicity of an area (determined by SAC prevalence
[19]) is an accurate estimate of PSAC burden is not fully understood and requires more research.
Studies in some endemic areas have shown that existing health systems can be tapped to improve
access to PSAC and nonenrolled SAC at primary and/or secondary school levels. For example,
studies in Zimbabwe have utilized the local primary health centers as a means to access PSAC,
showing high compliance even in follow-up studies [35,39,49]. In other countries, Child Health
Days offer a potential opportunity for easily reaching PSAC [17], as demonstrated in Uganda for
albendazole treatments [50]. Another approach is to empower health workers to identify and
treat nonspecific signs of suspected clinical cases of schistosomiasis in PSAC [48]. The caveat
here, however, will be the potential of providing praziquantel treatment for nonspecific clinical
symptoms due to other conditions aside from schistosomiasis. Of critical importance will be to
monitor and evaluate any changes and constraints that these strategies may cause to health sys-
tems already implementing other intervention programs. PSAC are currently not included in na-
tional or regional metrics on schistosomiasis, and they should be included in formal monitoring
and evaluation across a diversity of endemicities to address this critical gap in knowledge.
Improvements in Treatment Uptake among Adults Is Urgently Needed to Combat
Chronic Schistosomiasis
By contrast to PSAC, at-risk adults in high endemicity areas are currently eligible to receive treat-
ment annually during community-based MDA, but coverage of adults is significantly lower than
that of SAC [4]. A minority (43.8%) of the population eligible for schistosomiasis PC in sub-
Saharan Africa (does not include PSAC) were successfully treated in 2017, similar to global levels
described in the introduction – the majority were SAC (coverage 69.4%); only 13.4% of adults re-
quiring PC were treated [4]. Adults are not included in several national control programs despite a
high proportion of adults requiring PC across the region (Figure 1C). Notwithstanding insufficient
stocks of praziquantel, barriers to adult uptake of MDA include community perceptions of schis-
tosomiasis as a children’s disease, hesitancy to report symptoms of schistosomiasis due to fear
of stigma, failure to offer drugs to adults during MDA, nonspecific or mild symptoms, fear of side
effects, and difficulty seeking MDA if it requires time away from work [51–55]. Pregnant women
are frequently excluded from MDA, despite studies demonstrating the safety and efficacy of
praziquantel during pregnancy and lactation [56,57]. Many health practitioners and national policy
makers are reticent to support treatment of pregnant women [58]. With an average of 4.5 live
births per female across sub-Saharan Africa [14], a significant portion of the crucial years of a fe-
male’s adult life can be spent excluded fromMDA. These gaps in treatment coverage, especially if
individuals are systemically untreated, have significant clinical impacts, as discussed below, and
can play a major role in maintaining transmission even after decades of MDA [59,60]. Monitoring
efforts to measure treatment uptake, concurrent with parasitological surveys to measure preva-
lence and intensity, are necessary to improve effectiveness of current community-based MDA.
Additionally, we believe it is time for a re-evaluation of current MDA guidelines to ensure that ad-
olescents and adults who are infected across a range of endemicities are eligible to receive
treatment.
Morbidity in Adults
Female genital schistosomiasis (FGS) and male genital schistosomiasis (MGS) are gender-spe-
cific manifestations of schistosomiasis associated with pathology caused by the migration of586 Trends in Parasitology, July 2020, Vol. 36, No. 7
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Figure 2. Distribution of Populations and Schistosomiasis Burden across Age Groups in sub-Saharan Africa. (A) Growing populations in sub-Saharan Africa
mean that the population, on average, is very young [14]; the solid red rectangle indicates individuals eligible for school-basedmass drug administration (MDA), whereas the
dot-dash rectangle indicates those currently included in community-based MDA. (B) The majority of the population are in the adult age group (ages 15 and above).
(C) Prevalence of Schistosomamansoni acrossmajor age groups in a survey of ~10 000 individuals in Uganda (data from [15]). Peak prevalence in females occurs between
15 and 19 years, whereas males’ peak prevalence occurs from 20 to 29 years, and then falls in both sexes as they grow older. (D)Schistosomamansoni infection intensities
from the same population, showing that infection intensities peak at approximately the same age (or even older for females) and then decline more rapidly than prevalence.
Abbreviations: epg, eggs per gram; PSAC, preschool-aged children; SAC, school-aged children.
Trends in Parasitologyschistosome eggs through genital tissue. While most commonly observed with Schistosoma
haematobium infection, cases associated with Schistosoma mansoni infection have also been
described [61,62].
In approximately half of the girls andwomenwithS. haematobium infection, or an estimated 40million
girls and women in Africa [63], FGS causes gynecological morbidity marked by symptoms including
postcoital bleeding, genital itch, genital discharge, and infertility. The infection additionally has beenBox 2. Pediatric Praziquantel Consortium
Praziquantel is an existing drug approved for treatment of schistosomiasis and is currently licensed for ages 4 years and
older, although off-label informal use for younger children with infections is advised by WHO. To improve formal access to
treatment, the Consortium’s goal is to make an orally dispersible tablet (ODT) of praziquantel that is suitable for use and
dosing in children aged from 3months to 6 years. Phase I and II clinical trials are complete, and the Phase III trials of safety
and efficacy of the developed monoisomeric praziquantel formulation in ODT (150mg) for subsequent dosing at 50 mg/kg
are ongoing. The trials are comparing the new ODT with crushed or broken praziquantel tablets in the target age group.
Pending success in these trials, which will allow formal change in licensing of praziquantel, this pediatric praziquantel for-
mulation will help to alleviate the current health inequity in schistosomiasis control.
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mitted infection and lack of awareness of healthcare workers about this debilitating condition [54].
Even when FGS is suspected, confirmatory laboratory testing is limited by poor sensitivity [64].
Another broken connection is the interplay of FGS and menstrual hygiene management [65]. In addi-
tion to direct gynecological effects, FGS has also been associated with increased prevalence of HIV
infection [66,67] and S. haematobium infection with increased hazard of HIV acquisition in women
[68]. Evidence suggests that early, repeated praziquantel treatment in girls may have the potential
to reverse these gynecological abnormalities [69] and potentially to decrease the risk of HIV acquisition
in at-risk girls and women.
MGS was first described in 1911 by Madden in Egypt [70]. It has been found in 43% of partici-
pants in a small epidemiological study [71] and up to 58% of autopsy patients infected with
S. haematobium [72], but the majority of published research on MGS is case studies [73].
MGS causes genital or ejaculatory pain, abnormal ejaculate content, haemospermia, infertility,
enlarged genital organs, granulomatous infiltration, fibrosis, and calcifications [62,71,74,75].
Though praziquantel resolves some of the symptoms, the reversibility of chronic pathologies is
not yet known, and more frequent doses may be more efficacious [76]. The distribution and full
extent of MGS is unknown as there are challenges in the diagnosis – semen microscopy, in par-
ticular, has low sensitivity and is difficult to carry out in standard healthcare practice [77]. Other
prevalent co-occurring diseases, such as sexually transmitted infections and tuberculosis, pres-
ent symptomatology and pathologies similar to those of MGS, further complicating diagnosis.
While early studies suggested a relationship between MGS and HIV, more research is required
to understand the role of MGS in HIV acquisition and onward transmission [68,78–81].
For both MGS and FGS, awareness of these conditions, improved diagnosis, and timely treat-
ment are needed to alleviate the clinical burden of chronic infections and to address comorbidities
that they facilitate. Further operational and implementation research studies on FGS andMGS are
critically needed in order to address these neglected forms of schistosomiasis and understand
how improved uptake and frequency of treatment can prevent and reverse morbidity. Regular in-
clusion of adults in monitoring activities will improve understanding of the scope and distribution
of schistosomiasis in communities and help to target gender-specific interventions.
Opportunities for Strengthening Interventions in Adults
Numerous opportunities exist to improve access of MDA to adults [82], and local data
documenting the most significant barriers may be useful in designing the most effective strategies
for improvement in specific communities or regions. Some interventions likely to be successful in
many sites include optimizing selection and training for community drug distributors [83], provid-
ing health education about schistosomiasis [84] focusing on adults who have lived in villages for
prolonged periods [85], and targeting young adults in college or other youth settings [51,86]. Re-
peated MDA campaigns can lead to treatment fatigue [85], and low compliance may be low due
to nonspecific symptoms. Therefore, targeted treatment, including ‘test and treat’, may be a use-
ful tool in encouraging drug uptake in communities and has been used successfully in low-en-
demic settings [87]. Ensuring reliable availability of praziquantel in health centers will also
facilitate access to treatment outside of the often-narrow time window of MDA.
Reinfection still occurs even after treatment in adults. Even successfully delivered annual
praziquantel treatment may be insufficient; 40% of adult women in an endemic region who had
schistosome infections treated at baseline were found to be schistosome-infected at least
once during 12 months of follow-up [55]. These findings are supported by other studies in com-
munities with high water contact in adults [24,25], although reinfection occurs more often in SAC588 Trends in Parasitology, July 2020, Vol. 36, No. 7
Outstanding Questions
What are the most effective methods
to improve access to information and
treatment in groups already eligible for
MDA, including pregnant women and
unenrolled SAC?
How can infected individuals receive
treatment outside of MDA programs?
Can we identify characteristics of
communities where it is essential to
integrate control in PSAC and adult
age groups?
Can we include monitoring of all
age groups in schistosomiasis
programming so that PSAC and
adults are systematically included
in the evaluation of control effective-
ness and used to inform future con-
trol strategies?
Pending roll-out of the pediatric formu-
lation of the anthelmintic praziquantel,
what is the best way to quantify infec-
tion burden in PSAC to inform control
strategies? How can we leverage
existing health systems to improve
treatment access to this age group?
What mechanisms cause FGS and
MGS, and what interventions can pre-
vent these conditions?
If treatment is expanded to include all
age groups at risk, will there be
sufficient praziquantel available? And
if not, how can we produce and
access the higher numbers of
praziquantel tablets needed for this
wider treatment campaign?
Trends in Parasitologyand younger groups [10], potentially due to an increase in adult immunity towards reinfection.
Although treatment will not completely prevent morbidity due to reinfection, community-based
MDA is more cost-effective than school-based MDA in a range of settings [88,89] and there is
a reduced likelihood of reinfection in adults [25].
Treatment as a Complement to Integrated Methods for Interventions
Identifying communities with a persisting high prevalence of infection, determining the best
approaches to deliver drugs outside of the school environment, building capacity within health
centers, ensuring sufficient praziquantel availability, and targeted approaches to undertreated
age groups are all ways to improve existing MDA programs [26]. However, treatment with
praziquantel will not be sufficient for the sustainable control and elimination of schistosomiasis
in many areas [90]. Improved water, sanitation, and hygiene (WASH), behavior change, targeted
education, and snail control are all fundamental facets to ensuring that schistosome transmission
will reduce, and be ultimately eliminated, in endemic communities [91] and are cost-effective [92].
It is important that these additional interventions be deployed equitably so that benefits are
achieved throughout the lifespan of individuals. Precision mapping provides an innovative way
to better target interventions and allocate resources to focal transmission areas and the specific
species of Schistosoma to target [93]. Strengthening deployment while reducing the global bur-
den of disease will improve the financial sustainability of control programs.
Concluding Remarks
At any age, coming into contact with fresh water harboring cercariae can lead to schistosome
infection. Indeed, schistosomiasis can be pervasive, and it affects the world’s poor, who are com-
monly dependent on local water bodies and at risk for exposure, sometimes on a daily basis.
Whilst water contact patterns and immune status may change throughout life, there is an urgent
need to ensure that treatment is available to all age groups (see Outstanding Questions). MDA
with praziquantel, which is inexpensive and has a low side-effect profile, has focused primarily
on SAC but, as we strive for elimination, it is clear that widening this approach to include the entire
population at risk will be essential for success, and we should leave no one behind.
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